IL6 and ovarian serous adenocarcinoma: To evaluate the usefulness of the three IL-6-based classification, plasma samples from an independent cohort, including 25 patients with advanced stage high grade serous ovarian cancer, 25 patients with a benign ovarian mass and 19 healthy volunteers, were tested.